Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genenta Science SPA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GNTA
Nasdaq
8731
http://www.genenta.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genenta Science SPA (ADR)
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
- Feb 8th, 2024 10:00 am
Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
- Feb 3rd, 2024 12:06 pm
Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%
- Nov 14th, 2023 10:50 am
Genenta to Present at Upcoming Scientific and Investor Conferences
- Sep 6th, 2023 11:00 am
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
- Jul 28th, 2023 7:00 am
Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation
- Jul 8th, 2023 1:57 pm
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
- Jun 29th, 2023 11:00 am
Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company
- May 17th, 2023 10:34 am
Genenta to Provide Update on Lead Product Temferon™
- May 16th, 2023 11:00 am
Sidoti's Micro-Cap Virtual May Conference
- May 9th, 2023 11:15 am
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
- Apr 26th, 2023 11:00 am
Scroll